soul trial oral semaglutide cardiovascular outcomes nejm 2025 results Oral Semaglutide Reduces Cardiovascular Events in People with NEJM Editorial Fellow Harleen Marwah,

The results show immense favorability with the drug in the treatment of this weight-related concern despite its few gastrointestinal-related disorders

However, as with any supplement, side effects can occur, particularly at higher doses

You can review how Ozempic and Wellbutrin interact for related context, since bupropion raises some overlapping questions about combining antidepressants with GLP-1 treatment

Here, consistency is crucial

Some medical organizations have issued guidance recommending that diabetic patients be prioritized for limited Ozempic supplies, reflecting concern about diverting medications from their original therapeutic purpose

Here with me is Dr